KR970021071A - 항접착성 피페리딘 카르복실산 및 피롤리딘카복실산 - Google Patents
항접착성 피페리딘 카르복실산 및 피롤리딘카복실산 Download PDFInfo
- Publication number
- KR970021071A KR970021071A KR1019960044663A KR19960044663A KR970021071A KR 970021071 A KR970021071 A KR 970021071A KR 1019960044663 A KR1019960044663 A KR 1019960044663A KR 19960044663 A KR19960044663 A KR 19960044663A KR 970021071 A KR970021071 A KR 970021071A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- cooh
- pyranoside
- formula
- linked
- Prior art date
Links
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 title 1
- 230000000181 anti-adherent effect Effects 0.000 title 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 150000005846 sugar alcohols Polymers 0.000 claims abstract 2
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 claims 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- -1 pyranosyl radical Chemical class 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 102000003800 Selectins Human genes 0.000 claims 2
- 108090000184 Selectins Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000021164 cell adhesion Effects 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- HOVAGTYPODGVJG-BWSJPXOBSA-N (2r,3s,4s,5s)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-BWSJPXOBSA-N 0.000 claims 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 150000008448 D-mannosides Chemical group 0.000 claims 1
- 150000008489 L-fucosides Chemical group 0.000 claims 1
- 150000008449 L-mannosides Chemical group 0.000 claims 1
- 150000008451 L-rhamnosides Chemical group 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000021523 carboxylation Effects 0.000 claims 1
- 238000006473 carboxylation reaction Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000008223 ribosides Chemical group 0.000 claims 1
- 238000006798 ring closing metathesis reaction Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 150000002243 furanoses Chemical class 0.000 abstract 1
- 229920005646 polycarboxylate Polymers 0.000 abstract 1
- 150000003215 pyranoses Chemical class 0.000 abstract 1
- 150000003235 pyrrolidines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Abstract
본 발명은 모노 또는 폴리카복실레이트 피페리딘 또는 피롤리딘 유도체 및 쇄 또는 환 시스템을 통하여 연결된 피라노즈, 푸라노즈 또는 폴리알콜로 구성된 접합체에 관한 것이다. 피레리딘 유도체의 카복실 그룹은 직접 환 상에 위치될 수 있거나 짧은 쇄를 통하여 환에 연결될 수 있다. 추가로 본 발명은 이들 화합물의 제조와 약제 및 진단제의 제조를 위한 이들의 용도에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (27)
- 다음 화학식 (1)의 화합물.상기 식에서, Z는 피라노사이드, C6 위치를 통해 연결된 피라노실 라디칼, C6 위치를 통해 연결된 알킬 피라노사이드, 푸라노사이드, C5 위치를 통해 연결된 푸라노실 라디칼, C5 위치를 통해 연결된 알킬 푸라노사이드 또는 몇몇 바람직한 위치를 통해 A에 연결된 폴리알콜이고; A는 산소, -CH2- 또는 황이며; R1및 R2는 서로 독립적으로 수소, -(CH2)mX1또는 CH20(CH2)mX2(여기서, m은 정수 1 내지 20이다)이거나, 또는함께, 치환체 R4, R5또는 R6중 하나 이상을 가지는 5 또는 6원의 카보- 또는 헤테로사이클이고; E는 질소, 탄소 또는 -CH-이며; R3는 -(CH2)pCOOH, (-COOH)2, -(CH2)pCH(COOH)2, -(CH2)pCNH2(COOH)<SB2, -(CH2)pC(CH2-C6H5)(COOH)2, -CONHC(COOH)2(여기서, p는 정수 0 내지 10이다)이거나, 또는이고; q 및 r은 서로 독립적으로 정수 0 내지 3이며; n은 정수 1 내지 3인데, 단 q, r 및 n의 합은 4 또는 5이며; R4, R5및 R6는 서로 독립적으로 H, OH, -0(CH2)wX3또는 CH20(CH2)wX4(여기서, w는 정수 1 내지 18이다)이며; Y1및 Y2는 서로 독립적으로 산소, -NH- 또는 황이고; X1, X2, X3및 X4는 서로 독립적으로 수소, -NH2, -COOH, -OH, -CH2OH, CH2NH2, -C1-C20-알킬 또는 -C6-C10-아릴이다.
- 제1항에 있어서, R1및 R2가 함께 사이클로헥산 환을 형성하는 화합물.
- 제1항에 있어서, R1및 R2가 함께 사이클로펜탄 환을 형성하는 화합물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, A가 산소인 화합물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, Y1및 Y2가 산소인 화합물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, n이 1이고 q 및 r이 2인 화합물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, n 및 r이 1이고 q가 3인 화합물.
- 제1항 내지 제5항 중 어느 한 항에 있어서, n이 1이고 q가 0이며 r이 3인 화합물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, E가 -CH-이고, R3이 - (CH2)pCOOH이고 P가 0인 화합물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, E가 -CH-이고, R3이 - (CH2)pCH(COOH)2이고 P가 1인 화합물.
- 제1항 내지 제8항 중 어느 한 항에 있어서, E가 탄소이고 R3이 (-COOH)2인 화합물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, Z가 피라노사이드인 화합물.
- 제12항에 있어서, 피라노사이드가 L-푸코사이드인 화합물.
- 제12항에 있어서, 피라노사이드가 D-만노사이드인 화합물.
- 제12항에 있어서, 피라노사이드가 L-람노사이드인 화합물.
- 제12항에 있어서, 피라노사이드가 L-갈락토사이드인 화합물.
- 제12항에 있어서, 피라노사이드가 L-만노사이드인 화합물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, Z가 푸라노사이드인 화합물.
- 제18항에 있어서, 푸라노사이드가 리보사이드인 화합물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, Z가 C6위치를 통하여 연결된 D-만노실 라디칼인 화합물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, Z가 C6 위치를 통하여 연결된 메틸 D-만노사이드인 화합물.
- 제1항 내지 제11항 중 어느 한 항에 있어서, Z가 L-트레이트-1-일 라디칼인 화합물.
- 먼저, 2개 이상의 인접한 작용성 그룹 L1및 L2를 가지고 또한 치환체 R1및 R2를 가지는 화학식 (2)의 수용체의 작용성 그룹을 등량의 공여체를 통해, 0- 또는 S-글리코실화, 알킬화 또는 C-C 연결시켜, 경우에 따라 보호 그룹을 갖는 화학식 (3)의 활성 그룹 L3을 제공하고, 화학식 (4)의 중간체 화합물을 제조한 다음, 이를 화학식 (5)의 시약과 반응시켜 화학식 (6)의 활성화된 화합물을 수득하고, 이것을 모노- 또는 폴리카복실레이트화 사이클릭 아민 또는 이의 적합한 전구체와 반응시키고 경우에 따라 폐환 또는 카복실화한 후 또한 보호 그룹을 제거한 후에, 화학식 (1)의 화합물로 전환시키는 것을 포함하여, 제1항 내지 제22항 중 어느 한 항에 따른 화학식 (1)의 화합물의 제조 방법.상기 식에서, 라디칼 R1, R2, Y1, Y2, A 및 Z는 제1항에서 정의한 바와 같고, L4및 L5는 이탈 그룹을 나타낸다.
- 제1항 내지 제22항 어느 한 항에 따른 하나 이상의 화합물을 포함하는 약제.
- 질환에 의해서 영향받은 조직 내에서, 셀렉틴 수용체에 의해 매개되는 과잉의 세포 접착과 연관된 질환의 치료 또는 예방용 약제의 제조를 위한, 제1항 내지 제22항 중 어느 한 항에 따른 화합물의 용도.
- 제25항에 있어서, 질환이 심장혈관 질환인 용도.
- 질환에 의해서 영향받은 조직 내에서, 셀렉틴 수용체에 의해 매개되는 과잉의 세포 접착과 연관된 질환의 진단용 조성물의 제조를 위한, 제1항 내지 제22항 중 어느 한 항에 따른 화합물의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19537334.0 | 1995-10-09 | ||
| DE19537334A DE19537334A1 (de) | 1995-10-09 | 1995-10-09 | Antiadhäsive Piperidin- und Pyrrolidin-Carbonsäuren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970021071A true KR970021071A (ko) | 1997-05-28 |
Family
ID=7774241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960044663A KR970021071A (ko) | 1995-10-09 | 1996-10-09 | 항접착성 피페리딘 카르복실산 및 피롤리딘카복실산 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5739300A (ko) |
| EP (1) | EP0787739B1 (ko) |
| JP (1) | JPH09110834A (ko) |
| KR (1) | KR970021071A (ko) |
| CN (1) | CN1150155A (ko) |
| AT (1) | ATE231877T1 (ko) |
| AU (1) | AU6799796A (ko) |
| BR (1) | BR9605024A (ko) |
| CA (1) | CA2187392A1 (ko) |
| CZ (1) | CZ294096A3 (ko) |
| DE (2) | DE19537334A1 (ko) |
| HR (1) | HRP960459A2 (ko) |
| HU (1) | HUP9602745A3 (ko) |
| MX (1) | MX9604657A (ko) |
| NO (1) | NO964268L (ko) |
| PL (1) | PL316429A1 (ko) |
| SI (1) | SI9600296A (ko) |
| SK (1) | SK127796A3 (ko) |
| TR (1) | TR199600799A2 (ko) |
| ZA (1) | ZA968470B (ko) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1804299A (en) * | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| EP1534725A2 (en) | 2002-05-16 | 2005-06-01 | Glycomimetics, Inc. | Compounds and methods for inhibiting selectin-mediated function |
| WO2003106381A2 (en) | 2002-06-12 | 2003-12-24 | Exelixis, Inc. | Human adam-10 inhibitors |
| WO2004004636A2 (en) * | 2002-07-03 | 2004-01-15 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis |
| US20040219158A1 (en) * | 2003-05-02 | 2004-11-04 | Glycomimetics, Inc. | Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria |
| WO2005054264A2 (en) * | 2003-11-19 | 2005-06-16 | Glycomimetics, Inc. | Glycomimetic antagonists for both e- and p-selectins |
| EP1763533B1 (en) * | 2003-11-19 | 2008-01-09 | GlycoMimetics, Inc. | Specific antagonist for both e- and p-selectins |
| US8201377B2 (en) * | 2004-11-05 | 2012-06-19 | Faus Group, Inc. | Flooring system having multiple alignment points |
| WO2006127906A1 (en) * | 2005-05-25 | 2006-11-30 | Glycomimetics, Inc. | Heterobifunctional compounds for selectin inhibition |
| CA2618638C (en) * | 2005-08-09 | 2014-03-11 | Glycomimetics, Inc. | Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas |
| PT1934236E (pt) | 2005-09-02 | 2012-12-26 | Glycomimetics Inc | Inibidores de pan-selectina heterobifuncionais |
| WO2007143052A1 (en) * | 2006-06-01 | 2007-12-13 | Glycomimetics, Inc. | Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas |
| WO2008060378A2 (en) | 2006-10-12 | 2008-05-22 | Glycomimetics, Inc. | Glycomimetic replacements for hexoses and n-acetyl hexosamines |
| WO2008100453A1 (en) * | 2007-02-09 | 2008-08-21 | Glycomimetics, Inc. | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines |
| US8039442B2 (en) | 2007-07-18 | 2011-10-18 | Glycomimetics, Inc. | Compounds and methods for treatment of sickle cell disease or complications associated therewith |
| US8895510B2 (en) | 2008-04-08 | 2014-11-25 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| AU2009257536B2 (en) * | 2008-06-13 | 2015-07-02 | Glycomimetics, Inc. | Treatment of cancers of the blood using selected glycomimetic compounds |
| AU2010241807B2 (en) * | 2009-05-01 | 2014-08-14 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| EP3296310A1 (en) | 2011-12-22 | 2018-03-21 | GlycoMimetics, Inc. | E-selectin antagonist compounds, compositions, and methods of use |
| HUE038423T2 (hu) | 2012-12-07 | 2018-10-29 | Glycomimetics Inc | E-szelektin antagonistákat felhasználó vegyületek, készítmények és eljárások vérképzõ sejtek mobilizációjára |
| WO2016089872A1 (en) | 2014-12-03 | 2016-06-09 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
| US11045485B2 (en) | 2016-01-22 | 2021-06-29 | Glycomimetics, Inc. | Glycomimetic inhibitors of PA-IL and PA-IIL lectins |
| WO2017151708A1 (en) | 2016-03-02 | 2017-09-08 | Glycomimetics, Inc. | Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin |
| WO2018031445A1 (en) | 2016-08-08 | 2018-02-15 | Glycomimetics, Inc. | Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4 |
| WO2018068010A1 (en) | 2016-10-07 | 2018-04-12 | Glycomimetics, Inc. | Highly potent multimeric e-selectin antagonists |
| EP3596096A1 (en) | 2017-03-15 | 2020-01-22 | GlycoMimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| WO2019108750A1 (en) | 2017-11-30 | 2019-06-06 | Glycomimetics, Inc. | Methods of mobilizing marrow infiltrating lymphocytes and uses thereof |
| JP7304863B2 (ja) | 2017-12-29 | 2023-07-07 | グリコミメティクス， インコーポレイテッド | Ｅ－セレクチンおよびガレクチン－３のヘテロ二機能性阻害剤 |
| CA3091454A1 (en) | 2018-03-05 | 2019-09-12 | Glycomimetics, Inc. | Methods for treating acute myeloid leukemia and related conditions |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0671409A3 (de) * | 1994-03-11 | 1996-06-12 | Hoechst Ag | Malonsäurederivate mit antiadhäsiven Eigenschaften. |
-
1995
- 1995-10-09 DE DE19537334A patent/DE19537334A1/de not_active Withdrawn
-
1996
- 1996-09-26 AT AT96115414T patent/ATE231877T1/de not_active IP Right Cessation
- 1996-09-26 DE DE59610093T patent/DE59610093D1/de not_active Expired - Lifetime
- 1996-09-26 EP EP96115414A patent/EP0787739B1/de not_active Expired - Lifetime
- 1996-10-04 US US08/726,142 patent/US5739300A/en not_active Expired - Fee Related
- 1996-10-04 SK SK1277-96A patent/SK127796A3/sk unknown
- 1996-10-07 AU AU67997/96A patent/AU6799796A/en not_active Abandoned
- 1996-10-07 HU HU9602745A patent/HUP9602745A3/hu unknown
- 1996-10-07 HR HR19537334.0A patent/HRP960459A2/hr not_active Application Discontinuation
- 1996-10-07 TR TR96/00799A patent/TR199600799A2/xx unknown
- 1996-10-07 CN CN96113073A patent/CN1150155A/zh active Pending
- 1996-10-07 CZ CZ962940A patent/CZ294096A3/cs unknown
- 1996-10-07 PL PL96316429A patent/PL316429A1/xx unknown
- 1996-10-08 BR BR9605024A patent/BR9605024A/pt not_active Application Discontinuation
- 1996-10-08 CA CA002187392A patent/CA2187392A1/en not_active Abandoned
- 1996-10-08 SI SI9600296A patent/SI9600296A/sl unknown
- 1996-10-08 MX MX9604657A patent/MX9604657A/es unknown
- 1996-10-08 NO NO964268A patent/NO964268L/no unknown
- 1996-10-08 JP JP8267002A patent/JPH09110834A/ja active Pending
- 1996-10-08 ZA ZA968470A patent/ZA968470B/xx unknown
- 1996-10-09 KR KR1019960044663A patent/KR970021071A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2187392A1 (en) | 1997-04-10 |
| EP0787739B1 (de) | 2003-01-29 |
| SK127796A3 (en) | 1997-05-07 |
| HRP960459A2 (en) | 1998-02-28 |
| US5739300A (en) | 1998-04-14 |
| PL316429A1 (en) | 1997-04-14 |
| MX9604657A (es) | 1998-04-30 |
| HUP9602745A3 (en) | 1998-03-02 |
| HUP9602745A2 (en) | 1997-05-28 |
| BR9605024A (pt) | 1998-06-30 |
| ZA968470B (en) | 1997-04-09 |
| JPH09110834A (ja) | 1997-04-28 |
| NO964268D0 (no) | 1996-10-08 |
| TR199600799A2 (tr) | 1997-04-22 |
| CZ294096A3 (en) | 1997-04-16 |
| CN1150155A (zh) | 1997-05-21 |
| EP0787739A1 (de) | 1997-08-06 |
| DE19537334A1 (de) | 1997-04-10 |
| ATE231877T1 (de) | 2003-02-15 |
| AU6799796A (en) | 1997-04-17 |
| NO964268L (no) | 1997-04-10 |
| DE59610093D1 (de) | 2003-03-06 |
| HU9602745D0 (en) | 1996-11-28 |
| SI9600296A (en) | 1997-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970021071A (ko) | 항접착성 피페리딘 카르복실산 및 피롤리딘카복실산 | |
| RU2220141C2 (ru) | Производные бензотиепин-1,1-диоксидов, способ их получения и лекарственное средство | |
| EP0030377B1 (de) | 9-Chlor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel | |
| EP0716648B1 (de) | Neue 9-chlor-prostaglandin-derivate | |
| KR900018129A (ko) | 콘드로이틴 황산염, 데르마탄황산염 및 히알루론산의 술포아미노 유도체와 그 약제학적 성질 | |
| BR0014939A (pt) | Oligossacarìdeos, processo de preparação de oligossacarìdeos, composições farmacêuticas, e, utilização de oligossacarìdeos | |
| EP0069696A2 (de) | 9-Fluor-prostaglandinderivate, Verfahren zur Herstellung und Verwendung als Arzneimittel | |
| PT649854E (pt) | Bisconjugados compreendendo dois sacaridos e um espacador | |
| KR850004472A (ko) | 4h-3,i-벤즈옥사진-4-온 유도체의 제조방법 | |
| EP0198829A1 (de) | 9-halogen-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
| RU94044456A (ru) | Средство для подавления дисфункционального маточного кровотечения | |
| NO20001871L (no) | Nye 3,6-hemiacetaler fra klassen 9a-azalider | |
| KR900016098A (ko) | 카페인산의 유도체 및 이를 함유하는 약제학적 조성물 | |
| KR890016009A (ko) | 1,2,5,6-테트라히드로 피리딘유도체, 이들의 제조방법, 의약으로서 이들의 용도 및 이들을 함유하는 조성물 | |
| KR910004602A (ko) | 크로만 유도체 | |
| KR950018037A (ko) | 시알산 유도체 | |
| OA09022A (fr) | Nouveaux dérivés flavonoides pipérazyl-2 oxo-é éthylànes substitués, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. | |
| KR870011244A (ko) | 초과산화물 디스무타제 유도체의 제조방법 | |
| NO20000434L (no) | Lyksofuranosyl benzimidazoler som antivirale midler | |
| ATE3149T1 (de) | Isatinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
| ATE227734T1 (de) | 5'-substitutierte-ribofuranosyl benzimidazolen als antivirale. | |
| BR0109617A (pt) | Composição farmacêutica, oligossacarìdeo, processo de preparação de oligossacarìdeos, e, utilização de oligossacarìdeos | |
| CA1329591C (en) | Pharmaceutical products and new lactosyl compounds and the preparation thereof | |
| BRPI0715269A2 (pt) | composto, sal do composto, composiÇço farmacÊutica, mÉtodo para a fabricaÇço de uma composiÇço farmacÊutica, uso de um composto e mÉtodo para o tratamento de uma disfunÇço na coagulaÇço sanguÍnea | |
| ATE185795T1 (de) | Alkylsulfoacetat-zusammensetzungen und verfahren zu ihrer herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |